Guiding rapid expansion.
The directors who comprise our board are as passionate about innovation and as dedicated to the advancement of patient care as our leadership team is.
Each of these respected executives and entrepreneurs applies personal experience to further the progress of therapies in our pipeline.
Sean Brynjelsen
Chief Executive Officer & Director
More
Notable Experience
- Executive Vice President, Business Development at Sagent Pharmaceuticals, a generic injectable company acquired by Nichi-Iko Pharmaceutical Co.
- Senior Vice President, Global Business Development at Akorn, Inc., a pharmaceutical company specializing in ophthalmic and injectable products
- Product development, injectable pharmaceuticals at Baxter, Abbott, and Hospira
Education
- MBA, University of Notre Dame
- MS, Chemistry, University of Illinois
- BS, Chemistry, University of Illinois
Norbert Riedel, PhD
Chairman
CEO, Aptinyx
More
Notable Experience and Activities
- President & CEO at Naurex, acquired by Allergan and spun out into Aptinyx and its technology
- Corporate Vice President and Chief Science & Innovation Officer at Baxter International
- Head of Worldwide Biotechnology at Hoechst Marion Roussel (now Sanofi)
- Board member, Jazz Pharmaceuticals and the Illinois Biotechnology Innovation Organization
Education
- PhD, Biochemistry, University of Frankfurt
- Diploma, Biochemistry, University of Frankfurt
Charles J. Casamento
Executive Director & Principal, The Sage Group
More
Notable Experience and Activities
- Specializes in mergers, acquisitions, and partnerships between biotechnology companies and pharmaceutical companies
- President & CEO of Osteologix, Inc., a public biopharmaceutical company developing products to treat osteoporosis
- Chairman of the board, president, and CEO of Questcor Pharmaceuticals, Inc. (acquired by Mallinckrodt)
- Chairman of the board, president, and CEO of RiboGene, Inc. (merged with Cypros to form Questcor)
- Co-founder, president, and CEO of Interneuron Pharmaceuticals, Inc. (Indevus), a biopharmaceutical company acquired by Endo
- Senior Vice President, pharmaceuticals and biochemicals at Genzyme Corporation
- Vice president, business development and strategic planning, Critical Care Division at American Hospital Supply
- Senior management roles at Johnson & Johnson; Hoffmann-LaRoche, Inc.; Sandoz Inc.
- Board of Directors at Relmada Therapeutics; AzurRx BioPharma; International Stem Cell Corp
- Has sat on the boards of 12 public companies
- Director and Vice Chairman of The Catholic Medical Missions Board
- Guest lecturer and Science Council member at Fordham University
Education
- MBA, Iona College
- BS, Pharmacy, Fordham University
Paul V. Maier
Eton Pharmaceutical Audit Committee Chairman
More
Notable Experience and Activities
- Financial advisor to the life science industry
- CFO of Sequenom, Inc. and Ligand Pharmaceuticals Inc.
- Senior executive in biotechnology and specialty pharmaceutical companies
- Served on the boards of 8 companies
- Audit Committee Chair for 4 public life science companies
- Executive Partner at the College of William & Mary Mason School of Business
Education
- MBA, Harvard Business School
- BS, Business Logistics, Pennsylvania State University
Jenn Adams
Director
More
Notable Experience and Activities
- Healthcare leadership roles for over 30 years
- Extensive experience leading, transforming, and driving growth in both Fortune 500 public and private equity-backed companies, as well as deep expertise within the outsourced pharmaceutical services sector
- CEO of August Bioservices, a leading provider of research, development, and manufacturing services to pharmaceutical and biotechnology companies
- Served as Executive in Residence at Oak HC/FT
- SVP & President for the Clinical Product Solutions business at AmerisourceBergen
Education
- MBA, Kellogg School of Management, Northwestern University